Get the Stockscreener App
4.71
0.51%
-0.05
Aldeyra Therapeutics Inc stock is traded at $4.71, with a volume of 42,942.
It is down -0.51% in the last 24 hours and down -14.37% over the past month.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.
See More
Previous Close:
$4.76
Open:
$4.81
24h Volume:
42,942
Relative Volume:
0.09
Market Cap:
$283.46M
Revenue:
-
Net Income/Loss:
$-44.80M
P/E Ratio:
-5.2921
EPS:
-0.89
Net Cash Flow:
$-30.67M
1W Performance:
+10.90%
1M Performance:
-14.37%
6M Performance:
+20.19%
1Y Performance:
+94.08%
1-Day Range:
$4.71
$4.85
1-Week Range:
$4.09
$5.12
52-Week Range:
$2.43
$6.5476
Aldeyra Therapeutics Inc Stock (ALDX) Company Profile
Name
Aldeyra Therapeutics Inc
Sector
Industry
Phone
781-761-4904
Address
131 HARTWELL AVENUE, LEXINGTON, MA
Compare ALDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| ALDX | 4.71 | 283.46M | 0 | -44.80M | -30.67M | -0.89 |
| VRTX | 446.01 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 739.53 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 587.24 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.68 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.39 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-03-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-02-24 | Resumed | H.C. Wainwright | Buy |
| Apr-27-22 | Resumed | H.C. Wainwright | Buy |
| Feb-08-21 | Initiated | H.C. Wainwright | Buy |
| Dec-16-20 | Initiated | Berenberg | Buy |
| Oct-30-20 | Initiated | Jefferies | Buy |
| Oct-16-20 | Initiated | BTIG Research | Buy |
| Sep-22-20 | Initiated | Alliance Global Partners | Buy |
| May-12-20 | Initiated | Oppenheimer | Outperform |
| Dec-04-18 | Initiated | Citigroup | Buy |
| Sep-26-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Sep-13-18 | Initiated | Janney | Buy |
| Jan-26-18 | Initiated | Seaport Global Securities | Buy |
| Sep-26-16 | Initiated | H.C. Wainwright | Buy |
| Jul-01-16 | Initiated | Stifel | Buy |
| Jul-01-15 | Initiated | Canaccord Genuity | Buy |
| Mar-25-15 | Initiated | Chardan Capital Markets | Buy |
| Mar-20-15 | Reiterated | H.C. Wainwright | Buy |
| Nov-18-14 | Initiated | H.C. Wainwright | Buy |
| Jun-19-14 | Initiated | Aegis Capital | Buy |
View All
Aldeyra Therapeutics Inc Stock (ALDX) Latest News
ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap - MSN
Top US Penny Stocks To Watch In November 2024 - Simply Wall St
Aldeyra announces FDA acceptance of resubmitted reproxalap application - MSN
Aldeyra Therapeutics (ALDX) Refiles NDA for Innovative Dry Eye D - GuruFocus.com
5,578 Shares in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Bought by US Bancorp DE - Defense World
BTIG sets shares target with buy rating on Aldeyra, cites FDA read - Investing.com
Aldeyra Therapeutics Shares Up, FDA to Review New Drug Application - MarketWatch
FDA reviews Aldeyra's dry eye disease drug candidate By Investing.com - Investing.com Canada
Aldeyra announces FDA acceptance of resubmitted reproxalap application (NASDAQ:ALDX) - Seeking Alpha
FDA reviews Aldeyra's dry eye disease drug candidate - Investing.com
Aldeyra's Dry Eye Drug Gets FDA Review, Expands $400M AbbVie Partnership Deal | ALDX Stock News - StockTitan
What is Leerink Partnrs' Forecast for ALDX FY2024 Earnings? - MarketBeat
Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Short Interest Update - MarketBeat
Research Analysts Issue Forecasts for ALDX FY2028 Earnings - MarketBeat
Aldeyra Therapeutics CEO to Present at Jefferies London Healthcare Conference | ALDX Stock News - StockTitan
Aldeyra Therapeutics Insiders Who Sold Avert US$58m Market Cap Dip - Simply Wall St
Aldeyra’s FDA Resubmission And AbbVie Option Revitalize Reproxalap’s Prospects (ALDX) - Seeking Alpha
Nephrotic Syndrome Drugs Market Analysis of the Competitive - openPR
Is BellRing Brands (BRBR) Outperforming Other Medical Stocks This Year? - Yahoo Finance
(ALDX) Trading Advice - Stock Traders Daily
Aldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium during the OSN New York Retina 2024 Meeting - StockTitan
International Assets Investment Management LLC Buys 229,487 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - MarketBeat
Short Interest in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Increases By 13.3% - MarketBeat
(ALDX) Long Term Investment Analysis - Stock Traders Daily
Neuropathic Ocular Pain Pipeline Assessment 2024: Therapies, - openPR
Neuropathic Ocular Pain Pipeline Assessment 2024: Therapies, Clinical Trials, Therapies, and Key Companies Involved by DelveInsight | Ocular Therapeutix, Aldeyra Therapeutics, Aciex Therapeutics - Barchart
Allergic Conjunctivitis Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Bausch & Lomb Inc, Aldeyra Therapeutics, Vanda Pharma, OKYO - The Globe and Mail
Allergic Conjunctivitis Pipeline 2024: Clinical Trials - openPR
Aldyera therapeutics director Nancy Miller-Rich buys $10,446 in stock - Investing.com
(ALDX) Investment Analysis - Stock Traders Daily
Dimensional Fund Advisors LP Sells 210,153 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - MarketBeat
Nephrotic Syndrome Drugs Market Set for Rapid Expansion with - openPR
(ALDX) Proactive Strategies - Stock Traders Daily
American Century Companies Inc. Acquires 36,528 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
Renaissance Technologies LLC Sells 224,390 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - MarketBeat
Lexington biotech resubmits dry eye drug for FDA approval a year after rejection - The Business Journals
Aldeyra Resubmits New Drug Application for Reproxalap for Dry Eye Disease - MD Magazine
Aldeyra Therapeutics stock affirmed at Outperform on NDA submission By Investing.com - Investing.com Canada
Aldeyra resubmits dry eye treatment NDA to FDA By Investing.com - Investing.com Australia
Aldeyra Therapeutics Files Again for FDA OK of Dry-Eye Disease Treatment - MarketWatch
Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease - StockTitan
Aldeyra Therapeutics extends loan agreement terms - Investing.com India
Aldeyra Therapeutics extends loan agreement terms By Investing.com - Investing.com UK
Aldeyra Therapeutics, Inc. Enters into the Fourth Amendment to Loan and Security Agreement - Marketscreener.com
Aldeyra shares hold Outperform rating on pipeline progress By Investing.com - Investing.com Canada
What was Aldeyra Therapeutics Inc (ALDX)’s performance in the last session? - US Post News
Aldeyra Therapeutics Inc (ALDX) rating upgrades by Oppenheimer - Knox Daily
Market Watch Highlights: Aldeyra Therapeutics Inc (ALDX) Ends on an Upturn Note at 5.50 - The Dwinnex
Aldeyra Therapeutics Inc (ALDX) Performance and Fundamentals Dashboard tells a completely different story - SETE News
Perceptive Advisors LLC Buys 682,265 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - MarketBeat
(ALDX) Trading Signals - Stock Traders Daily
Aldeyra Therapeutics Inc Stock (ALDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):